Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.
复制标题
DOI：
10.3390/v6072735
复制
发表时间：
2014-07-17
期刊：
影响因子：
--
通讯作者：
Volz A
中科院分区：
文献类型：
--
作者：
Altenburg AF;Kreijtz JH;de Vries RD;Song F;Fux R;Rimmelzwaan GF;Sutter G;Volz A
由流感病毒、人类副流感病毒(HPIV)、呼吸道合胞病毒(RSV)和冠状病毒引起的呼吸道病毒感染是严重威胁公众健康的疾病。目前，还没有针对hPIV、RSV和冠状病毒的许可疫苗，而且现有的季节性流感疫苗具有相当大的局限性。关于大流行防备，重要的是制定程序，迅速作出反应，并在短时间内生产针对这些呼吸道病毒的量身定制的疫苗。此外，特别是对于流感，迫切需要开发一种通用疫苗，以诱导对各种亚型流感病毒的广泛保护性免疫。改良痘苗病毒安卡拉(MVA)是一种复制缺陷的病毒载体，有望成为疫苗平台。MVA可以编码一个或多个外来抗原，因此起到多价疫苗的作用。该载体可用于生物安全级别1，具有内在佐剂能力，并诱导体液和细胞免疫反应。然而，有一些实际和监管问题需要解决，以便在大流行边缘的短时间内开发基于MVA的疫苗。在这篇综述中，我们讨论了有希望的新型流感病毒疫苗靶点以及MVA在针对各种呼吸道病毒的疫苗开发中的应用。
Respiratory viruses infections caused by influenza viruses, human parainfluenza virus (hPIV), respiratory syncytial virus (RSV) and coronaviruses are an eminent threat for public health. Currently, there are no licensed vaccines available for hPIV, RSV and coronaviruses, and the available seasonal influenza vaccines have considerable limitations. With regard to pandemic preparedness, it is important that procedures are in place to respond rapidly and produce tailor made vaccines against these respiratory viruses on short notice. Moreover, especially for influenza there is great need for the development of a universal vaccine that induces broad protective immunity against influenza viruses of various subtypes. Modified Vaccinia Virus Ankara (MVA) is a replication-deficient viral vector that holds great promise as a vaccine platform. MVA can encode one or more foreign antigens and thus functions as a multivalent vaccine. The vector can be used at biosafety level 1, has intrinsic adjuvant capacities and induces humoral and cellular immune responses. However, there are some practical and regulatory issues that need to be addressed in order to develop MVA-based vaccines on short notice at the verge of a pandemic. In this review, we discuss promising novel influenza virus vaccine targets and the use of MVA for vaccine development against various respiratory viruses.
登录
查看更多内容
影响因子：
5.5
作者：
Boyd, Amy C.;Ruiz-Hernandez, Raul;Peroval, Marylene Y.;Carson, Connor;Balkissoon, Devanand;Staines, Karen;Turner, Alison V.;Hill, Adrian V. S.;Gilbert, Sarah C.;Butter, Colin
通讯作者：
Butter, Colin
影响因子：
12.4
作者：
Antrobus, Richard D.;Berthoud, Tamara K.;Gilbert, Sarah C.
通讯作者：
Gilbert, Sarah C.
影响因子：
5.4
作者：
Bender, BS;Rowe, CA;Small, PA
通讯作者：
Small, PA
影响因子：
29.7
作者：
Blum JS;Wearsch PA;Cresswell P
通讯作者：
Cresswell P
流感病毒疫苗：2009年H1N1大流行的教训。
影响因子：
5.9
作者：
Broadbent, Andrew J.;Subbarao, Kanta
通讯作者：
Subbarao, Kanta